https://doi.org/10.55788/24c0400c
The phase 3 BOREAS trial demonstrated the superiority of dupilumab over placebo in terms of reducing exacerbations and improving lung function, quality-of-life, and symptoms in patients with COPD and type 2 inflammation [1]. The 939 participants enrolled in BOREAS were randomised 1:1 to dupilumab or placebo. The current post-hoc analysis investigated treatment- by-biomarker interaction effects on the annualised rate of moderate or severe acute exacerbations of COPD [2].
“The dupilumab treatment effect increased with higher baseline blood eosinophil counts,” said Dr Stephanie Christenson (University of California San Francisco, CA, USA):
- 300 cells/ μL category: 25% improvement versus placebo
- 500 cells/ μL category: 29% improvement versus placebo
- 700 cells/ μL category: 39% improvement versus placebo
- 900 cells/ μL category: 52% improvement versus placebo; P-value for interaction=0.006
Likewise, higher baseline FeNO levels were associated with a larger treatment effect. In the ≥20 ppb category, exacerbations were reduced by 29% in participants receiving dupilumab versus those receiving placebo. In the ≥40 ppb category, the corresponding reduction in exacerbations was 42% (P-value for interaction=0.043). “Compared with placebo, dupilumab reduced moderate-to-severe exacerbations across all measured biomarker levels,” concluded Dr Christenson. “The treatment effect was significantly larger in patients with higher baseline blood eosinophil counts and in those with higher baseline FeNO levels.”
- Bhatt S, et al. N Engl J Med 2023;389:205-214.
- Nicola A, et al. Baseline blood eosinophils and FeNO predict dupilumab response in COPD with type 2 inflammation: phase 3 BOREAS trial. C95: New clinical trial results in chronic lung disease. ATS 2024, 17–22 May, San Diego, USA.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Two regimens deliver high sputum conversion rates in M. xenopi pulmonary infection Next Article
NOTUS: Dupilumab safe and efficacious in COPD with type 2 inflammation »
« Two regimens deliver high sputum conversion rates in M. xenopi pulmonary infection Next Article
NOTUS: Dupilumab safe and efficacious in COPD with type 2 inflammation »
Table of Contents: ATS 2024
Featured articles
NOTUS: Dupilumab safe and efficacious in COPD with type 2 inflammation
Sulthiame may be the next treatment for OSA
Miscellaneous Topics
Pirfenidone may alleviate disease burden in DRCB
Can mindfulness reduce depression and anxiety in ICU survivors?
Exercise and diet improve functional status in PAH
Idiopathic Pulmonary Fibrosis
STARSCAPE: Zinpentraxin alfa does not ameliorate health status in IPF
COPD
COURSE: Encouraging results for tezepelumab in COPD
Ensifentrine delays transition from GOLD B to GOLD E in COPD
NOTUS: Dupilumab safe and efficacious in COPD with type 2 inflammation
BOREAS: Blood eosinophil count and FeNO levels predictive of dupilumab response in COPD
Respiratory Infections
Two regimens deliver high sputum conversion rates in M. xenopi pulmonary infection
Patient-reported outcomes improve practice in MAC lung disease
Novel RSV vaccine to prevent serious respiratory illness
Asthma
UCAP: Identify and treat undiagnosed COPD or asthma
Structural and functional lung improvement with dupilumab in asthma
Obstructive Sleep Apnea
Is the Apnea Hypopnea Index ready to be replaced?
Does PAP therapy truly reduce mortality in OSA?
Sulthiame may be the next treatment for OSA
Related Articles
August 17, 2022
Asthma increases risks around delivery
September 22, 2020
Night-to-night variability in respiratory events among apnea patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com